To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: FDA Approves Lactose-Free Formulation of Antispasmodic/Anticholinergic, Pamine (Methoscopolamine) URL: http://www.pslgroup.com/dg/1FF81A.htm Doctor's Guide June 28, 2001
FAIRFIELD, NJ -- June 28, 2001 -- Bradley Pharmaceuticals, Inc. announced today that the Food and Drug Administration (FDA) approved a lactose-free formulation of Pamine® (methscopolamine bromide), the company's fast-growing antispasmodic/anticholinergic therapy. Although the original Pamine formula contained only a very small amount of lactose that would not have adversely affected most lactose-intolerant patients, Bradley chose to create this new formulation to ensure that this therapy was the best possible product. In a recent survey, gastroenterologists estimate that 10 to 40 percent of their patients with gastrointestinal (GI) hypermotility are lactose-intolerant. It is estimated that between 30 and 50 million Americans are lactose-intolerant, and some studies report that incidences of lactose intolerance are very high in certain ethnic populations. According to these reports, as many as 75 percent of African-Americans and 90 percent of Asians may be lactose-intolerant. Daniel Glassman, President and CEO of Bradley Pharmaceuticals, Inc., stated, "We have improved the formulation of Pamine because we recognize the special needs of lactose-intolerant patients. Our goal is to reduce the possibility of lactose interfering with the relief Pamine can provide. New and improved Pamine offers lactose-intolerant patients the safest and most effective antispasmodic/anticholinergic that we can make."
SOURCE: Bradley Pharmaceuticals, Inc. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.